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ABSTRACT
Introduction: Resveratrol (3,5,40-
trihydroxystilbene) is an antioxidant that has
multiple biologic effects including
antimicrobial properties. Acne vulgaris is a
disease of the pilosebaceous unit, characterized
by an inflammatory host immune response to
the bacteria Propionibacterium acnes (P. acnes).
This study sought to determine whether
resveratrol may be a potential treatment for
acne vulgaris.
Methods: Colony-forming unit (CFU) assays
together with transmission electron microscopy
using P. acnes treated with resveratrol or benzoyl
peroxide were used to assess antibacterial effects.
Blood was drawn from healthy human
volunteers, and 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) assays were used to assess
cytotoxicity in monocytes and keratinocytes.
Results: Resveratrol demonstrated sustained
antibacterial activity against P. acnes, whereas
benzoyl peroxide, a commonly used
antibacterial treatment for acne, demonstrated
a short-term bactericidal response. A
combination of resveratrol and benzoyl
peroxide showed high initial antibacterial
activity and sustained bacterial growth
inhibition. Electron microscopy of P. acnes
treated with resveratrol revealed altered
bacterial morphology, with loss of membrane
definition and loss of well-defined extracellular
fimbrial structures. Resveratrol was less
cytotoxic than benzoyl peroxide.
Conclusion: The sustained antibacterial
activity and reduced cytotoxicity versus
benzoyl peroxide demonstrated by resveratrol
in this study highlight its potential as a novel
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therapeutic option or adjuvant therapy in the
treatment of acne vulgaris.
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INTRODUCTION
Acne is the most prevalent skin disease in the
world, affecting 85% of adolescents and over
10% of adults [1]. In the USA, it represents a
tremendous economic burden with total costs
exceeding $3 billion per year [2]. Antibiotics are
efficient against sensitive Propionibacterium
acnes, but resistance has developed due to
monotherapy and overuse [3]. Other
treatments such as retinoids and benzoyl
peroxide are limited by patient compliance
due to undesirable side effects such as
irritation [4]. Benzoyl peroxide is highly
effective as an antimicrobial in vitro [5] and
in vivo [6], and it is a first-line drug for the
treatment of acne due to its direct bactericidal
and comedolytic properties. Although no
known bacterial resistance has been reported
to benzoyl peroxide [7, 8], its side effects still
limit its use. Thus, the need exists for new
efficacious treatments with fewer side effects.
Already, newer topical combination therapies
have been developed to reduce the
concentration of benzoyl peroxide through its
combination with other anti-acne compounds
[9].
Resveratrol (3,5,40-trihydroxystilbene) may
be a useful anti-acne treatment. It is a potent
antioxidant and anti-inflammatory compound
that has been shown to have antineoplastic and
wound-healing activities [10]. It has been
demonstrated to inhibit inflammatory
markers activation protein-1 (AP-1) and
nuclear factor-kappaB (NF-jB), both of which
have been implicated in the formation of
inflammatory acne lesions [11]. Resveratrol is
also antimicrobial, demonstrating antiviral,
antifungal, antibacterial, and antiprotozoal
activity [12–14], and has been shown to
inhibit keratinocyte proliferation, which
contributes to follicular obstruction in the
formation of acne lesions [15]. Few studies
have evaluated resveratrol’s application as a
treatment for acne vulgaris, although one
clinical study has previously demonstrated the
potential efficacy of resveratrol in the treatment
of acne vulgaris [16]. Additionally, an in vitro
study showed that resveratrol has antimicrobial
activity against P. acnes [17].
The present study further investigated the
potential of resveratrol as a treatment for acne.
It sought to determine the in vitro effects of
resveratrol on P. acnes growth and survival,
while further assessing the antimicrobial
mechanism of action of resveratrol and its
cytotoxic effects. It also determined the
efficacy of utilizing resveratrol as part of a
combination therapy with benzoyl peroxide.
METHODS
Reagents
Resveratrol and benzoyl peroxide were obtained
from Sigma-Aldrich (St. Louis, MO, USA). The
compounds were dissolved in dimethyl
sulfoxide (DMSO) and diluted to 1% DMSO in
experiments, to minimize the effect of DMSO.
Colony-Forming Unit assay
Antibacterial activity of resveratrol was
determined by colony-forming unit (CFU)
assays. P. acnes ATCC (American type cell
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culture) strain 6919 (a ribotype 1 [18] MLST4
1A1 strain [19]) was grown anaerobically at
37 C in reinforced clostridial media (Oxoid,
Basingstoke, Hampshire, UK) for 3 days and
collected in the late exponential phase of
growth by centrifugation. Bacteria were
washed with pH 7 sodium phosphate buffer
supplemented by 0.03% trypticase soy media
and quantified by reading with a
spectrophotometer at 600 nm and applying a
conversion of 1 9 108 bacteria = 1 absorbance
unit. Approximately, 1.33 9 106 CFUs of
bacteria were then added to 1 mL reinforced
clostridial media. Samples were incubated
anaerobically at 37 C, with aliquots
periodically withdrawn and plated on brucella
agar with 5% sheep blood supplemented with
hemin and vitamin K (Remel, Lenexa, KS, USA).
Plates were incubated anaerobically at 37 C for
3 days, and individual P. acnes colonies were
counted to determine the concentration.
Electron Microscopy
Propionibacterium acnes at 107 CFU/mL were
incubated with either 1 mg/mL of resveratrol
or benzoyl peroxide for 24 h. Bacteria were
washed three times with phosphate buffered
saline (PBS) and resuspended in PBS with 2%
glutaraldehyde. Samples were fixed for 5 min
with 0.05% OsO4, dehydrated in graded
ethanol, and embedded in Eponate 12 (Ted
Pella, Redding, CA, USA). A Reichert-Jung
Ultracut E ultramicrotomeTM (Leica, Buffalo
Grove, IL, USA) was used to cut 60–70 nm
slices which were picked up on formvar-coated
copper grids. Uranyl acetate and Reynolds lead
citrate were used for staining, and stained
samples were visualized at 80 kV on a JEOL
100CX electron microscopeTM (Peabody, MI,
USA).
MTS Assay
Blood was drawn from healthy human
volunteers recruited by the laboratory with
no skin conditions, including acne, and who
had not suffered any illness within 2 weeks of
the blood draw date. Peripheral blood
mononuclear cells were isolated by use of a
Ficoll-Paque (Pharmacia, New York, NY, USA)
gradient and allowed to adhere for 2 h in RPMI
media (Gibco, Grand Island, NY, USA)
supplemented with 1% fetal bovine serum
(FBS) (Omega Scientific, Tarzana, CA, USA) in
96-well plates (Costar, Tewksbury, MA, USA).
Cells were washed 39 with Roswell Park
Memorial Park Institute (RPMI) media to
obtain adherent monocytes. Monocytes were
then incubated at 37 C in 100 lL RPMI media
supplemented with 10% FBS. The HaCaT cell
line of human keratinocytes was cultured in
100 lL HaCaT media and incubated at 37 C in
96-well plates (Costar). To evaluate human
monocyte and human keratinocyte viability
after incubation with resveratrol or benzoyl
peroxide, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) cytotoxicity assays were
performed. After 16 h of incubation with
resveratrol or benzoyl peroxide, 20 lL MTS
assay reagent (Promega, Madison, WI, USA)
was added to each well, and the monocyte and
keratinocyte cells were allowed to incubate for
*4 h at 37 C. The 490 nm absorbance of each
well was then determined using a microtiter
plate reader, with absorbance proportional to
the number of viable monocyte and
keratinocyte cells in each treatment, as
previously described [20]. Student’s T test was
used for statistical analysis to determine if
differences between resveratrol and benzoyl
peroxide-treated cells were significant.
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Compliance with Ethics Guidelines
Study protocol for withdrawal of blood from
healthy volunteers was approved by the
Institutional Review Board at the University of
California, Los Angles. All procedures followed
were in accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national) and
with the Helsinki declaration of 1975, as revised in
2000 and 2008. Informed consent was obtained
from all patients for being included in the study.
RESULTS
Resveratrol has Antibacterial Activity
Against P. acnes
The effect of resveratrol on P. acnes growth was
visually demonstrated by incubating P. acnes
bacteria with various concentrations of
resveratrol for 48 h in reinforced clostridial
media before spot plating. At a concentration
of at least 50 lg/mL, resveratrol demonstrated
significant inhibition of P. acnes growth (Fig. 1).
Resveratrol at 25 lg/mL had only a small
inhibitory effect.
Resveratrol and Benzoyl Peroxide have
Different Antibacterial Characteristics
To determine the antibacterial kinetics of
resveratrol, benzoyl peroxide, and a
combination of both on P. acnes growth, P.
acnes was incubated with these treatments in
reinforced clostridial media, and the
concentration of bacteria was determined after
1, 2, 3, 7, and 10 days. Resveratrol demonstrated
low bactericidal activity, but significant and
sustained growth inhibition at concentrations
of 100 lg/mL and shorter term growth
inhibition at 50 lg/mL (Fig. 2a).
In contrast, benzoyl peroxide demonstrated
significant differences in bactericidal kinetics
when compared to resveratrol. High bactericidal
activity was noted initially, but there was no
antibacterial activity observed after the first
24 h (Fig. 2b). P. acnes recovered from benzoyl
peroxide treatment and achieved maximum
growth rate by the second day, irrespective of
benzoyl peroxide concentration. Results from
the combination therapy of resveratrol and
benzoyl peroxide reflected the antibacterial
kinetics of each individual treatment (Fig. 2c).
As demonstrated with benzoyl peroxide alone,
the combination treatment showed high initial
antibacterial activity. Combination treatment
also demonstrated the longer term inhibitory
effects shown by resveratrol monotherapy.
Combination therapy, therefore, resulted in a
much lower concentration of P. acnes over the
course of the study than with either treatment
alone.
A comparison of each treatment group at a
concentration of 75 lg/mL highlighted the
Fig. 1 Resveratrol has antimicrobial activity against P.
acnes. Propionibacterium acnes was incubated with various
concentrations of resveratrol for 48 h and plated at
different dilutions demonstrating reduced bacterial colony
count at higher concentrations of resveratrol
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short-term bactericidal activity of benzoyl
peroxide, the sustained inhibitory activity of
resveratrol, and the enhanced activity of
resveratrol and benzoyl peroxide combination
therapy (Fig. 2d).
Resveratrol Alters the Membrane
and Structure of P. acnes
To further investigate the mechanism by which
resveratrol inhibits P. acnes growth, this study
examined the bacterium using transmission
electron microscopy (Fig. 3). Structural
alterations were noted in the bacteria treated
with resveratrol, with loss of membrane
definition due to intramembranous edema and
loss of well-defined extracellular fimbrial
structures. Intracellular buildup of a dense
substance was also found in some bacteria
treated with resveratrol.
Resveratrol has Lower Cytotoxicity
than Benzoyl Peroxide to Human
Monocytes and Keratinocytes
This study evaluated the cytotoxic effects of
benzoyl peroxide compared to resveratrol via
the MTS assay for human monocytes (Fig. 4a)
Fig. 2 Antimicrobial effects of resveratrol and benzoyl
peroxide over time. P. acnes was incubated in reinforced
clostridial media in the presence of resveratrol (a), benzoyl
peroxide (b), or a combination of both treatments (c).
Aliquots were removed at several time points and plated in
triplicate to determine the number of CFUs. A comparison
of each treatment group at 75 lg/mL is also displayed (d).
CFU colony-forming unit
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and keratinocytes (Fig. 4b). Benzoyl peroxide
was significantly more toxic than resveratrol to
monocytes (p\0.001 for all concentrations
tested, Student’s t test), resulting in over 90%
cell death at 10 lg/mL, while resveratrol
resulted in less than 40% cell death at the
same concentration. These effects were less
pronounced in keratinocytes (p\0.01 for all
concentrations tested, Student’s t test), where
both compounds had lower cytotoxicity.
Nonetheless, benzoyl peroxide treatment
resulted in 20–30% more cell death at all
concentrations tested in keratinocytes.
DISCUSSION
Acne vulgaris is the most common skin disease,
affecting millions of people worldwide [21].
Unfortunately, bacterial antibiotic resistance
and severe side effects limit the efficacy of
current treatments [22].
Resveratrol has a favorable safety profile and
is an anti-inflammatory and antimicrobial
compound. Thus, this study investigated the
potential of resveratrol as an antibacterial agent
for the treatment for acne vulgaris.
The results from this study demonstrated the
strong antibacterial activity of resveratrol at
concentrations of at least 50 lg/mL (Fig. 1).
These findings are consistent with prior studies
which have demonstrated inhibition of P. acnes
biofilm formation at slightly higher
concentrations of 200 lg/mL [23]. By further
investigating the nature of this antibacterial
activity, we found that resveratrol is
bacteriostatic in nature, possessing strong
inhibitory activity that limits the growth of P.
acnes (Fig. 2a). Its bactericidal activity was
relatively weak in terms of reduction of viable
bacteria, but the antibacterial activity was
sustained over time. This indicates that
resveratrol creates a gradual disruption of
normal bacterial cellular function, resulting in
cell death over a period of several days. Our
findings suggest that resveratrol reaches a
critical concentration around 50–75 lg/mL, at
which point a threshold for major growth
inhibition is passed and resveratrol becomes
bactericidal for a sustained period. In contrast,
benzoyl peroxide’s bactericidal activity was
strong initially, but was not sustained beyond
the first 24 h (Fig. 2b). This is in accordance
with benzoyl peroxide’s mechanism of action,
whereby free radicals are formed via
symmetrical fission, resulting in a short half-
life [24].
When both resveratrol and benzoyl peroxide
were combined, benzoyl peroxide’s strong
bactericidal effect coupled with resveratrol’s
high inhibitory activity resulted in low levels
of bacteria throughout the experiment (Fig. 2c).
Thus, this combination shows promise for
clinical treatment of acne vulgaris.
Fig. 3 Electron microscopy demonstrating antimicrobial
effect of resveratrol. Electron microscopy images of P. acnes
left untreated (a, b) or incubated for 24 h (c, d) with
resveratrol. Images were taken at 910,000 magnification
(a, c) or 929,000 magnification (b, d). Scale bar is 1 lm
(a, c) or 1/2 lm (b, d)
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Electron microscopy of P. acnes treated with
resveratrol revealed altered bacterial
morphology, with the bacteria displaying
intramembranous edema and disrupted
intracellular structural integrity (Fig. 3). As a
membrane permeable compound, this innate
characteristic of resveratrol may allow it to alter
the bacterial membrane structure of P. acnes and
disrupt intracellular machinery.
Benzoyl peroxide was found to be highly
cytotoxic to monocytes and keratinocytes,
potentially explaining the irritation found
with topical benzoyl peroxide regimens
(Fig. 4). Resveratrol was significantly less
cytotoxic, which may translate to decreased
irritation in vivo. A pilot study investigating
topical resveratrol treatment in acne found no
cutaneous side effects from resveratrol [16].
Additionally, one study demonstrated that
macrophages treated with resveratrol
maintained viability via a toll-like receptor 4
(TLR4)-dependant mechanism if also treated
with lipopolysaccharide [25], indicating that
resveratrol may be less cytotoxic to cells in the
presence of P. acnes.
A combination therapy of resveratrol and
benzoyl peroxide may allow for a significant
reduction of the benzoyl peroxide
concentration compared to current benzoyl
peroxide-based treatments, minimizing side
effects. However, this study was in vitro,
which does not necessarily translate to success
in the clinic. Concentrations used in vitro may
not accurately reflect effective in vivo
concentrations necessary for the treatment of
acne vulgaris. In vivo studies are needed to
evaluate the efficacy of resveratrol and benzoyl
peroxide in combination for the treatment of
acne vulgaris.
CONCLUSION
Resveratrol’s anti-inflammatory and
antibacterial properties demonstrated here
in vitro may address some of the pathogenic
mechanisms in the formation of acne. Already,
clinical studies have shown the beneficial
effects of resveratrol in the treatment of acne
[16]. However, acne is a multifactorial disease,
attributed also to sebum production [26], which
Fig. 4 Cytotoxicity of benzoyl peroxide and resveratrol.
Primary human monocytes (a) or keratinocytes (b) were
incubated with resveratrol and benzoyl peroxide for 16 h.
The percentages of viable cells were assessed in triplicate by
MTS assay. Statistics show comparison between resveratrol
and benzoyl peroxide group at each concentration by
Student’s t test, **(p\0.01), ***(p\0.001)
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is not currently known to be addressed by
resveratrol, and which may therefore limit its
use as a monotherapy in the treatment of acne.
Since resveratrol and benzoyl peroxide operate
with different antibacterial kinetics and
mechanisms, they may complement each
other in a combination treatment in vivo,
leading to enhanced clinical outcomes.
Overall, the data in this study indicates that
resveratrol may be a novel therapeutic option or
useful adjuvant therapy for the treatment of
acne vulgaris.
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